Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

Oncogene - 27 Apr 2006

Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, Månsson W, Fioretos T, Höglund M

Abstract excerpt

We used gene expression profiling, mutation analyses of FGFR3 and TP53, and LOH analyses of chromosome 9 and the TP53 region on chromosome arm 17p, to molecularly characterize 75 Ta and T1 bladder carcinomas. We identified four major cellular processes related to cell cycle, protein synthesis, immune response, and extra cellular components that contribute to the expressional heterogeneity of early-stage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 17
Share to Chromosomes, Human, Pair 9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Loss of Heterozygosity

Share to Neoplasm Recurrence, Local

Share to Oligonucleotide Array Sequence Analysis

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 16532037
DOI: 10.1038/sj.onc.1209249

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.PMID 16532037Read ↗

In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report.Semantic proximity Read ↗

FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.Semantic proximity Read ↗

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.Semantic proximity Read ↗

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.Semantic proximity Read ↗

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 yearsSemantic proximity Read ↗

Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.Semantic proximity Read ↗

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.Semantic proximity Read ↗

Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction.Semantic proximity Read ↗

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.Semantic proximity Read ↗

Molecular Basis of Urinary Bladder CancerSemantic proximity Read ↗

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.Semantic proximity Read ↗

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.